Home Sulfonamines 157212-55-0
157212-55-0,MFCD09751188
Catalog No.:AA001P85

157212-55-0 | 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide hydrate

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$7.00   $5.00
- +
50mg
98%
in stock  
$15.00   $11.00
- +
100mg
98%
in stock  
$24.00   $17.00
- +
1g
98+%
in stock  
$163.00   $114.00
- +
5g
98%
in stock  
$219.00   $153.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA001P85
Chemical Name:
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide hydrate
CAS Number:
157212-55-0
Molecular Formula:
C27H31N5O7S
Molecular Weight:
569.6293
MDL Number:
MFCD09751188
SMILES:
OCCOc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cc1)C(C)(C)C)c1ncccn1.O
Properties
Properties
 
BP:
742.3°C at 760 mmHg  
Form:
Solid  
MP:
107-109°C  
Storage:
Keep in dry area;2-8℃;  

Computed Properties
 
Complexity:
839  
Covalently-Bonded Unit Count:
2  
Heavy Atom Count:
40  
Hydrogen Bond Acceptor Count:
12  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
11  

Downstream Synthesis Route

[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]

[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]

[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]

[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]

150728-13-5   
bosentanmonohydrate 

[1]OrganicPreparationsandProceduresInternational,2013,vol.45,p.510-514

[2]OrganicPreparationsandProceduresInternational,2016,vol.48,p.481-491

[3]OrganicPreparationsandProceduresInternational,2016,vol.48,p.481-491

[4]OrganicPreparationsandProceduresInternational,2016,vol.48,p.481-491

Literature

Title: Dhillon S, et al. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2009;9(5):331-50.

Title: Akamata K, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther. 2014 Apr 3;16(2):R86.

Title: Iglarz M, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014 Nov 24;118(2):333-9.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:157212-55-0 Molecular Formula|157212-55-0 MDL|157212-55-0 SMILES|157212-55-0 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide hydrate